Impact of WBC on Patients With Metabolic or Neurological Diseases or Fibromyalgia (WBC-MeNeFi)

Launched by ISTITUTO AUXOLOGICO ITALIANO · Jul 1, 2022

Keywords

ClinConnect Summary

This clinical trial, called WBC-MeNeFi, is looking at how whole-body cryostimulation (WBC) might help people with obesity, fibromyalgia, and certain neurological conditions like Parkinson's disease and Multiple Sclerosis. In this study, participants will undergo 10 sessions of WBC, which involves briefly exposing the body to extremely cold temperatures. Researchers want to see if this treatment can reduce pain, fatigue, and inflammation, while also improving physical and mental well-being. The trial aims to include around 300 participants who are adults aged 18-65 with a body mass index (BMI) over 35.

To participate, individuals must not have severe psychiatric issues, recent respiratory or heart problems, or certain other health conditions. Those who join the trial will follow a rehabilitation program that includes diet, physiotherapy, and exercise, and half of the participants will also receive the WBC sessions. Throughout the study, doctors will monitor various health factors, such as body composition and blood pressure, to understand the overall effects of WBC. It’s an exciting opportunity for eligible participants to possibly improve their health and quality of life!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • both sexes
• • age 18-65 yrs
• • BMI \> 35 kg/m2
• Exclusion Criteria:
• • severe psychiatric conditions
• • acute respiratory disease
• • acute cardiovascular disease
• • unstable hypertension
• • cold intolerance
• • claustrophobia
• • pregnancy
• • recent modification of usual drug treatment
• • previous treatment with WBC
• • weight loss in the last 3 months
• • body temperature greater than 37.5°C.